Therefore, the primary aim of our study was to use Leukadherin‐1 to explore how CR3 activation modifies NK cell cytokine release in response to innate immune stimuli, in a way that might be relevant to SLE disease mechanisms. Here, CRIPTO3 is linked to systemic lupus erythematosus.